' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis
Bolik, J; Krause, F; Stevanovic, M; Gandrass, M; Thomsen, I; Schacht, SS; Rieser, E; Mueller, M; Schumacher, N; Fritsch, J; Wichert, R; Galun, E; Bergmann, J; Roeder, C; Schafmayer, C; Egberts, JH; Becker-Pauly, C; Saftig, P; Lucius, R; Schneider-Brachert, W; Barikbin, R; Adam, D; Voss, M; Hitzl, W; Krueger, A; Strilic, B; Sagi, I; Walczak, H; Rose-John, S; Schmidt-Arras, D
J EXP MED. 2021; 219(1): e20201039
Originalarbeiten (Zeitschrift)


Bergmann Jürgen
Hitzl Wolfgang


Metastasis is the major cause of death in cancer patients. Circulating tumor cells need to migrate through the endothelial layer of blood vessels to escape the hostile circulation and establish metastases at distant organ sites. Here, we identified the membrane-bound metalloprotease ADAM17 on endothelial cells as a key driver of metastasis. We show that TNFR1-dependent tumor cell-induced endothelial cell death, tumor cell extravasation, and subsequent metastatic seeding is dependent on the activity of endothelial ADAM17. Moreover, we reveal that ADAM17-mediated TNFR1 ectodomain shedding and subsequent processing by the gamma-secretase complex is required for the induction of TNF-induced necroptosis. Consequently, genetic ablation of ADAM17 in endothelial cells as well as short-term pharmacological inhibition of ADAM17 prevents long-term metastases formation in the lung. Thus, our data identified ADAM17 as a novel essential regulator of necroptosis and as a new promising target for antimetastatic and advanced-stage cancer therapies. Metastasis is the leading cause of death in cancer patients. We discovered that proteolytic processing of endothelial TNFR1 by the metalloprotease ADAM17 is essential for metastases formation. Based on our findings, we present a novel therapeutic approach to target metastasis.